The State of Bone Health in mCRPC: ERA-223 Results Revealed

Daniel George | November 06, 2018

At the 2018 meeting of the European Society of Medical Oncology (ESMO), Matthew Smith, MD, PhD, presented the highly anticipated results of ERA-223, a phase III trial of abiraterone acetate prednisone (AAP) combined with radium-223 or placebo in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)1. Radium-223 is the alpha-


Daniel George

Daniel George, MD is Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine and leads the Duke Prostate and Urologic Cancer Center. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology. Daniel George has led the Duke site for the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium since 2006.

State-of-the-industry video lectures by leading urology experts
Conference Coverage
Recent data from conferences worldwide

ESMO 2018 Prostate Cancer

SUO 2017 - Prostate Cancer

SIU 2017

ESMO 2017 Prostate Cancer

CUA 2017


ASCO 2017 Prostate Cancer

IPCU 2017 Prostate Cancer

AUA 2016 CRPC w/ bone metastases

EAU 2016 - Prostate Cancer

ASCO GU 2016 mCRPC Treatment

ASCO GU 2016 Prostate Cancer

An extensive resource of papers on urological diseases and conditions

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.